Ironwood Pharmaceuticals, Inc.IRWDNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P44
Within normal range
vs 2Y Ago
-0.3x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -2.69% |
| Q3 2025 | -3.87% |
| Q2 2025 | -14.80% |
| Q1 2025 | 8.04% |
| Q4 2024 | -14.87% |
| Q3 2024 | -1.85% |
| Q2 2024 | 17.71% |
| Q1 2024 | -27.64% |
| Q4 2023 | 10.53% |
| Q3 2023 | -97.13% |
| Q2 2023 | 8856.50% |
| Q1 2023 | 24.29% |
| Q4 2022 | -9.62% |
| Q3 2022 | 0.81% |
| Q2 2022 | 2.49% |
| Q1 2022 | -65.64% |
| Q4 2021 | 188.74% |
| Q3 2021 | -10.33% |
| Q2 2021 | -33.84% |
| Q1 2021 | 13.01% |
| Q4 2020 | -25.01% |
| Q3 2020 | 1.19% |
| Q2 2020 | -23.52% |
| Q1 2020 | 5.61% |
| Q4 2019 | -3.68% |
| Q3 2019 | -4.20% |
| Q2 2019 | -46.73% |
| Q1 2019 | 21.95% |
| Q4 2018 | -5.39% |
| Q3 2018 | 20.19% |
| Q2 2018 | 6.65% |
| Q1 2018 | -9.00% |
| Q4 2017 | 8.23% |
| Q3 2017 | -0.75% |
| Q2 2017 | 10.81% |
| Q1 2017 | -12.33% |
| Q4 2016 | 2.44% |
| Q3 2016 | 18.45% |
| Q2 2016 | -0.50% |
| Q1 2016 | 15.26% |